Journal of Alzheimer's disease reports最新文献

{"title":"A study on comprehensive bibliometric analysis of natural medicines for Alzheimer's disease (1999-2025).","authors":"Yue Chen, Huihuang Shi, Sicheng Chen, Zhu Li","doi":"10.1177/25424823261478276","DOIUrl":"10.1177/25424823261478276","url":null,"abstract":"<p><strong>Background: </strong>Natural medicines have low toxicity, multi-target effects and long-term clinical use. They inhibit amyloid-β (Aβ) deposition, regulate tau phosphorylation, and exert anti-inflammatory and antioxidant activities, matching Alzheimer's disease (AD) complex pathogenesis. Supported by the World Health Organization, they are promising alternatives to current symptomatic AD drugs that cannot stop disease progression.</p><p><strong>Objective: </strong>AD poses a growing global neurodegenerative burden, but systematic bibliometric analysis of natural medicines against AD remains lacking. This study aimed to reveal research trends, core contributors, hotspots and mechanisms from 1999 to 2025.</p><p><strong>Methods: </strong>Literature data were retrieved from the Web of Science Core Collection (WOSCC) database (1999-2025) using a combined subject term search strategy. VOSviewer 1.6.20 was used for collaborative network analysis (countries, institutions, authors) and keyword co-occurrence analysis; CiteSpace 6.3.R1 was applied for keyword burst detection.</p><p><strong>Results: </strong>Global publications on natural medicines against AD showed phased growth: slow growth (1999-2009), rapid growth (2011-2018), and explosive growth (2020-present). China led in publications; India had the strongest international collaboration. Top co-cited journals included <i>Journal of Ethnopharmacology</i>, and key cited literatures focused on natural medicines' anti-AD effects. Keyword analysis revealed core hotspots: oxidative stress, amyloid-beta, neuroinflammation, and emerging technologies. Core anti-AD mechanisms of natural medicines included inhibiting Aβ aggregation, regulating tau phosphorylation, anti-neuroinflammation, and gut-brain axis modulation. Numerous typical compounds showed potential but faced slow clinical translation.</p><p><strong>Conclusions: </strong>China is a core contributor. Research has shifted to molecular mechanisms and clinical translation, with network pharmacology, molecular docking and gut-brain axis as frontiers. Future efforts require interdisciplinary cooperation and large-sample trials.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261478276"},"PeriodicalIF":2.8,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caregiver burden, not patient cognitive impairment, predicts adherence to donepezil transdermal patch in Alzheimer's disease: A retrospective real-world study.","authors":"Ryuji Yajima, Takanobu Ishiguro, Makoto Michikawa, Satoshi Naruse","doi":"10.1177/25424823261468306","DOIUrl":"https://doi.org/10.1177/25424823261468306","url":null,"abstract":"<p><strong>Background: </strong>The donepezil transdermal patch is a useful option for Alzheimer's disease (AD) patients with poor oral adherence. However, treatment discontinuation due to skin irritation or management difficulties remains a clinical challenge.</p><p><strong>Objective: </strong>To identify predictive factors for the successful continuation of the donepezil transdermal patch in a real-world setting.</p><p><strong>Methods: </strong>A retrospective review included 26 AD patients newly prescribed or switched to the donepezil patch at a dementia center. Patients were divided into continuation (n = 15) and discontinuation (n = 11) groups based on a 12-week cutoff. We evaluated baseline demographics, Mini-Mental State Examination (MMSE), Clinical Dementia Rating-Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale-Cognitive Subscale for Activities of Daily Living (ADL-Cog), and caregiver burden using the 8-item Zarit Burden Interview (Zarit-8). Multivariate logistic regression identified risk factors for discontinuation.</p><p><strong>Results: </strong>Univariate analysis showed no significant differences between groups in age (p = 0.855), MMSE (p = 0.677), CDR-SB (p = 0.762), and ADL-Cog (p = 0.826). Although the mean Zarit-8 score was higher in the discontinuation group (14.00 ± 10.70 versus 7.86 ± 5.55, p = 0.171), this lacked statistical significance. However, multivariate regression revealed a higher Zarit-8 score was a significant independent predictor of discontinuation after adjusting for age (p = 0.038, OR = 1.134).</p><p><strong>Conclusions: </strong>Caregiver burden, rather than patient cognitive function or impairment in activities of daily living, significantly predicts discontinuation of the transdermal patch. To the best of our knowledge, no previous studies have utilized the Zarit burden scale as a clinical predictor of pharmacological adherence. Assessing caregiver reserve before introduction is crucial for maintaining adherence.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261468306"},"PeriodicalIF":2.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between transthyretin levels and Alzheimer's disease: A meta-analysis.","authors":"Bing-Qiu Li, Fang-Yu Li, Ling-Zhi Xu, Ying Li, Jian-Ping Jia","doi":"10.1177/25424823261478024","DOIUrl":"https://doi.org/10.1177/25424823261478024","url":null,"abstract":"<p><strong>Background: </strong>Transthyretin (TTR) has been implicated in amyloid-β (Aβ) binding, cerebrospinal fluid homeostasis, and neurodegenerative processes in Alzheimer's disease (AD), but clinical evidence regarding its levels in AD and mild cognitive impairment (MCI) remains inconsistent.</p><p><strong>Objective: </strong>This meta-analysis aimed to clarify the association between blood/cerebrospinal fluid (CSF) TTR levels and AD/MCI.</p><p><strong>Methods: </strong>Following the PRISMA guidelines, this meta-analysis systematically identified and included 18 eligible studies from databases including PubMed, Web of Science, Embase, and Cochrane Library.</p><p><strong>Results: </strong>Random-effects meta-analysis showed lower TTR levels in AD versus healthy controls (HC) (Hedges' g = -0.77, 95% CI: -1.50, -0.04; p = 0.04), with no significant differences in MCI versus HC. Subgroup analyses confirmed a significant reduction in TTR levels across multiple dimensions: 1) sample types (serum); 2) population characteristics (age difference < 5 years and sex difference ≥ 10%); and 3) detection methods (immunoassay). Multivariate meta-regression with region, sample source, detection technology, and female ratio difference as covariates, accounted for 36.81% of the between-study heterogeneity. Sensitivity analysis verified result robustness, and publication bias was resolved after excluding an outlier study.</p><p><strong>Conclusions: </strong>Lower TTR levels are significantly associated with AD. This finding suggests that TTR warrants further investigation as a candidate biomarker for AD, although prospective studies are needed to validate its clinical utility.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261478024"},"PeriodicalIF":2.8,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory epilepsy-derived transcriptomic projection reveals region-sensitive molecular remodeling in Alzheimer's disease.","authors":"Nannan Pan, Penghui Cao, Cuiling Zhang, Fengchun Wu, Yuping Ning","doi":"10.1177/25424823261483598","DOIUrl":"10.1177/25424823261483598","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) is frequently accompanied by seizures or subclinical epileptiform activity, but the transcriptomic context linking AD-related neurodegeneration with epilepsy-related network dysfunction remains unclear.</p><p><strong>Objective: </strong>To apply an exploratory epilepsy-derived directional transcriptomic projection framework to examine region-sensitive molecular organization in AD brain tissues.</p><p><strong>Methods: </strong>A directional reference was generated from GSE268714 by defining seizure onset zone (SOZ)-upregulated and SOZ-downregulated genes from an unpaired exploratory SOZ-versus-non-involved zone (NIZ) contrast, because patient-level identifiers were not recoverable. This reference was projected onto AD cohorts GSE5281, GSE132903, and GSE48350. EpilepsyScore was calculated as ssGSEA_Up minus ssGSEA_Down. In GSE5281, primary inference was restricted to region-stratified analyses.</p><p><strong>Results: </strong>Region-stratified analyses showed lower EpilepsyScore values across several AD-relevant regions, with the clearest separation in the middle temporal gyrus (MTG). Within MTG, continuous module-level associations with synaptic and glia-associated programs were directionally consistent but not statistically significant. Median-based grouping was used only for exploratory visualization and pathway-level contrast. External cohorts showed directionally concordant but context-dependent support. Matched random-signature benchmarks were not significant, indicating that EpilepsyScore should not be interpreted as an epilepsy-specific molecular signature.</p><p><strong>Conclusions: </strong>This study provides a hypothesis-generating cross-disease projection framework for exploring region-sensitive transcriptomic organization in AD. Future cell-type, spatial, and mechanistic evaluation is required.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261483598"},"PeriodicalIF":2.8,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between different types of tea consumption frequency and sleep quality with cognitive function among older adults in Qingdao rural area.","authors":"Ling Zhang, Wenqi Zhao, Zhenxue Song, Jingyi Zhang, Yuanjun Zeng, Jianguo Xie, Yuchi Meng, Murong Cheng, Dongfeng Zhang, Suyun Li","doi":"10.1177/25424823261479949","DOIUrl":"https://doi.org/10.1177/25424823261479949","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have shown that tea consumption frequency or sleep quality is independently associated with cognitive function, but the combined association remains unclear.</p><p><strong>Objective: </strong>To investigate the individual and combined associations between tea consumption frequency and sleep quality with cognitive function and analyze whether this association is modified by gender and age.</p><p><strong>Methods: </strong>The cross-sectional study involved 646 participants from 17 villages in Jimo District, Qingdao, in 2022. Data on tea consumption frequency were collected via a questionnaire. Cognitive function and sleep quality were assessed through the Montreal Cognitive Assessment and Pittsburgh Sleep Quality Index, respectively. Linear regression models were used to analyze associations, with a combined variable for tea consumption frequency and sleep quality constructed to evaluate their combined association. Stratified analysis and interaction tests assessed the moderating effects of gender and age.</p><p><strong>Results: </strong>Higher consumption frequency of green tea (β (95% CI): 0.97 (0.23, 1.70)) or black tea (β (95% CI): 0.78 (0.08, 1.48)) was positively associated with cognitive function. Moreover, higher consumption frequency of green tea combined with good sleep quality was significantly associated with optimal cognitive function (β (95% CI): 1.17 (0.10, 2.31)). Stratified analysis revealed no significant modifying effects of gender or age on the aforementioned associations.</p><p><strong>Conclusion: </strong>Increased consumption frequency of green tea, alongside maintaining good sleep quality, is associated with enhanced cognitive function. These findings highlight the value of modifiable lifestyle factors in promoting cognitive health.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261479949"},"PeriodicalIF":2.8,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain single-cell transcriptome-informed Mendelian randomization identifies potential druggable therapeutic targets for Alzheimer's disease.","authors":"Renjun Huang, Liqing Guan, Yang Chen, Qiang Jiao, Weirong Yin, Haixia Zhou","doi":"10.1177/25424823261478529","DOIUrl":"https://doi.org/10.1177/25424823261478529","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline, accounting for 60-70% of all dementia cases. The limitations of current therapies and the complexity of its multifaceted pathological mechanisms underscore the urgent need to identify candidate therapeutic targets.</p><p><strong>Objective: </strong>This study aims to systematically identify brain cell type-specific candidate druggable targets for Alzheimer's disease by integrating brain single-cell expression quantitative trait loci (sc-eQTL) data with large-scale genome-wide association studies (GWAS) using Mendelian randomization (MR) and colocalization analysis.</p><p><strong>Methods: </strong>This study integrates sc-eQTL data with large-scale GWAS to systematically assess the causal relationships between gene expression in eight brain cell types and AD risk using MR analysis and colocalization analysis. Target functionality was further analyzed through KEGG pathway analysis and the STRING protein interaction network.</p><p><strong>Results: </strong>MR analysis prioritized 46 genetically supported candidate druggable genes (FDR < 0.05), of which 10 gene-cell type pairs corresponding to 9 unique genes showed colocalization support. Cell type-specific analysis suggested that these genetically supported associations were restricted to specific brain cell types. Protein-protein interaction analysis with clinical AD drug targets showed that 13% of the candidate targets (6/46) had direct network connections with approved AD drug targets, suggesting potential pharmacological relevance.</p><p><strong>Conclusions: </strong>This study provides a brain cell type-resolved genetic prioritization framework for AD, nominating genetically supported candidate druggable targets and linking them to neurodegenerative and immune-related pathways. This framework may help generate hypotheses for future experimental validation and drug development.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261478529"},"PeriodicalIF":2.8,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma p-tau217 for detecting Aβ-PET positivity and tracking early amyloid accumulation in cognitively unimpaired ADNI participants.","authors":"Emadoddin Kazemi","doi":"10.1177/25424823261478592","DOIUrl":"10.1177/25424823261478592","url":null,"abstract":"<p><strong>Background: </strong>Amyloid-β (Aβ) accumulation begins before cognitive impairment, highlighting the need for scalable blood-based biomarkers to identify individuals at risk during the preclinical stage of Alzheimer's disease.</p><p><strong>Objective: </strong>To evaluate whether plasma %p-tau217 detects Aβ-PET positivity and whether longitudinal plasma %p-tau217 change is associated with early Aβ accumulation in cognitively unimpaired participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI).</p><p><strong>Methods: </strong>This retrospective longitudinal study included 98 cognitively unimpaired ADNI participants with plasma %p-tau217, plasma Aβ_42/40, Aβ-PET, and clinical/genetic data. Aβ-PET positivity was defined as Centiloid (CL) ≥ 40. Among participants with baseline Aβ-PET <40 CL, participant-specific annual slopes for Aβ-PET CL and plasma biomarkers were estimated from matched longitudinal measurements using linear mixed-effects models. Regression and receiver operating characteristic analyses assessed associations with Aβ-PET change and discrimination of Aβ-PET positivity and Aβ accumulator status.</p><p><strong>Results: </strong>Plasma %p-tau217 showed excellent discrimination of Aβ-PET positivity (area under the curve (AUC) = 0.962) and yielded a higher AUC than plasma Aβ_42/40. In participants with baseline Aβ-PET <40 CL, longitudinal plasma %p-tau217 slope was the only plasma biomarker independently associated with annual Aβ-PET CL increase in fully adjusted models (β = 1.38; FDR-adjusted p < 0.001). Plasma %p-tau217 slope also yielded a higher AUC for Aβ accumulator status than baseline plasma %p-tau217.</p><p><strong>Conclusions: </strong>Plasma %p-tau217 is a strong blood-based biomarker for detecting Aβ-PET positivity in cognitively unimpaired individuals. Longitudinal plasma %p-tau217 change provides additional information beyond baseline plasma biomarkers and may support enrichment or monitoring strategies in Alzheimer's disease prevention trials, pending validation in larger independent cohorts.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261478592"},"PeriodicalIF":2.8,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age specification matters? A multi-cohort evaluation of age specification and follow-up duration in the performance of midlife dementia risk scores.","authors":"Md Hamidul Huque, Kaarin J Anstey","doi":"10.1177/25424823261478253","DOIUrl":"10.1177/25424823261478253","url":null,"abstract":"<p><strong>Background: </strong>The heterogeneous performance of dementia and Alzheimer's disease risk scores makes it difficult to identify tools suitable for supporting risk reduction and prevention strategies. Although multiple factors may contribute, we hypothesized that differences in age specification and study design are the primary contributors to this variability.<b>Objective:</b> To evaluate how age specification and length of follow-up affect the performance of three midlife risk scores: CogDrisk-ML, CAIDE, and UKBDRS.</p><p><strong>Methods: </strong>Longitudinal data were drawn from the ARIC, UK Biobank, and Whitehall II cohorts. Participants free of dementia at baseline were included. Baseline variables were used to calculate each risk score. Risk prediction was evaluated using Cox proportional hazards models with three age specifications: UKBDRS (continuous), CogDrisk-ML (categorical: 40-49, 50-54, 55-59, 60-64 years), and CAIDE (categorical age: <47, 47-53, >53 years). Predictive accuracy was assessed using Harrell's C-statistics and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Across all cohorts and risk scores, excluding age from risk scores resulted in similar C-statistics. In age- and sex-only models, continuous age produced the highest Harrell's C-statistics (95% CI) [ARIC: 0.71 (0.68, 0.73); UK Biobank: 0.78 (0.77, 0.79), and Whitehall II: 0.75 (0.62, 0.88)], followed by categorical age specifications. Compared with continuous age, categorical specifications reduced C-statistics, with the largest reduction for CAIDE. Shorter follow-up yielded higher but less precise C-statistics.</p><p><strong>Conclusions: </strong>Age specification strongly influences dementia risk model performance, especially with shorter follow-up, with continuous age yielding the highest accuracy. Our findings emphasize that differences in dementia risk prediction performance are driven primarily by age specification and cohort age structure rather than intrinsic superiority of individual risk tools.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261478253"},"PeriodicalIF":2.8,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of HIV infection with dementia and cognitive impairment: A systematic review and meta-analysis.","authors":"Shuolong Li, Xinyue Yin, Daiyu Song, Guoyong Ding","doi":"10.1177/25424823261478284","DOIUrl":"https://doi.org/10.1177/25424823261478284","url":null,"abstract":"<p><strong>Background: </strong>With the widespread use of antiretroviral therapy, people living with HIV (PLWH) are experiencing increased life expectancy, accompanied by a growing burden of age-related comorbidities. Cognitive impairment and dementia have been increasingly reported among PLWH; however, epidemiological evidence regarding their association remains inconsistent.</p><p><strong>Objective: </strong>This systematic review and meta-analysis aimed to evaluate the association between HIV infection and the risk of dementia and cognitive impairment.</p><p><strong>Methods: </strong>We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library from inception to March 4, 2026 for cohort studies investigating the association between HIV infection and dementia or cognitive impairment. Study selection, data extraction, and quality assessment using the Newcastle-Ottawa Scale were independently conducted by two reviewers. Heterogeneity across studies was assessed using <i>Q</i> test and <i>I²</i> statistics. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using fixed- or random-effects models as appropriate. Subgroup, sensitivity, and publication bias analyses were performed.</p><p><strong>Results: </strong>A total of 9 articles were eligible for this analysis. The pooled results showed that HIV infection was significantly associated with an increased risk of dementia and cognitive impairment (RR=2.07, 95% CI: 1.35, 3.17). Substantial heterogeneity was observed across studies (<i>I²</i> =93.7%). Subgroup analyses suggested that publication year, baseline immunological status, and age distribution might partially explain the observed heterogeneity. Sensitivity analysis confirmed the robustness of the findings, and no significant publication bias was detected.</p><p><strong>Conclusions: </strong>This meta-analysis suggests that HIV infection is associated with an increased risk of dementia and cognitive impairment.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261478284"},"PeriodicalIF":2.8,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Donanemab-associated clinical improvement in Alzheimer's disease presenting predominantly with neuropsychiatric symptoms: A case report.","authors":"Yehao Jiang, Huamei Lin, Bo Hong, Ling Yue","doi":"10.1177/25424823261478025","DOIUrl":"10.1177/25424823261478025","url":null,"abstract":"<p><p>Late-life depression may mask Alzheimer's disease (AD). We report a 78-year-old man with treatment-refractory depressive and anxiety symptoms accompanied by paroxysmal somatic attacks, unresponsive to psychotropic treatment and modified electroconvulsive therapy. Ultimately, biomarker evaluation confirmed AD pathology, and donanemab was initiated. Follow-up amyloid positron emission tomography demonstrated marked amyloid clearance, particularly in the frontal lobe, accompanied by concurrent improvement in depressive symptoms, cognition, and reduced somatic attacks. This case suggests that anti-amyloid therapy may benefit AD patients presenting with refractory neuropsychiatric symptoms, potentially related to frontal amyloid clearance, underscoring the importance of AD screening in resistant late-life depression.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261478025"},"PeriodicalIF":2.8,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}